체외진단 시행 건수(2024-2029년)

IVD Test Procedure Volumes, 2024-2029

US $ 6,300 ￦ 8,736,000

Online Access (Single User License)

PDF 보고서를 1분이 열람(다운로드 불가)할 수 있는 라이선스입니다. 인쇄는 1회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 9,450 ￦ 13,105,000

Online Access & PDF Download (10 Users)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 인쇄는 10회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 12,600 ￦ 17,473,000

Online Access & PDF Download (Unlimited Users)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

급속히 진화하는 시장으로서 2024년 체외진단(IVD) 시장은 신기술, 진화하는 헬스케어 지출, 정밀진단에 대한 수요의 급증에 의해 촉진되며 성장할 것으로 보이고 있습니다.

체외진단 시행 건수에 대해 조사했으며, 2024-2029년 동향을 유형별, 지역별, 국가별로 분석합니다. 셀프 테스트부터 전문적인 POC(Point-of-Care), 임상화학, 혈액학까지 모든 것을 다루고 있습니다.

목차

제1장 개요

제2장 서론

• 개요
• 업계 동향
• COVID-19
• 인구 동향
• 세계의 인구와 고령화
• 인원 삭감
• 만성질환의 증가
• 맞춤형 의료
• 새로운 감염증의 위협
• 진드기 매개성 질환(TBD)
• 지카열
• 샤가스
• 뎅기열
• 에볼라
• 치쿤구니야 열
• 중동 호흡기 증후군 코로나바이러스(MERS-CoV)
• 마버그
• SARS-CoV-2(COVID-19)
• 원숭이두창
• 신흥 국가 및 신흥 시장

제3장 IVD 검사 부문

• IVD 검사 동향
• 부문 성장 예측
• POC 테스트
• 임상화학
• 면역측정
• 질량분석(면역)
• 분자 어세이
• 혈액학
• 응고
• 기존 미생물학
• 혈액형
• 조직학/세포학
• 부문 제품 판매

제4장 세계의 IVD 시장

• 전반
• 북미
• 미국
• 캐나다
• 멕시코, 중남미
• 브라질
• 멕시코
• 기타 중남미
• 서유럽
• 프랑스
• 독일
• 이탈리아
• 스페인
• 영국
• 기타 서유럽
• 동유럽
• 러시아
• 기타 동유럽
• 아시아태평양
• 중국
• 일본
• 기타 아시아 국가 및 지역
• 중동
• 터키
• 기타 중동
• 아프리카

제5장 POC(Point-of-Care) 시술

• 검사 유형별 세계 POC 검사 건수
• POC 셀프 테스트
• 기존 혈당치 모니터링 활동
• 연속 혈당 모니터링
• 임신과 생식 능력 검사
• 응고 검사
• 변잠혈 검사
• 남용 약물 검사
• 필로리균 검사
• HIV 검사
• 감염증
• 콜레스테롤 검사
• POC 검사
• 가격 동향

제6장 임상화학 검사 시술

• 검사 유형
• 일반화학
• 혈액가스와 전해질
• 요검사
• 임상화학 제품의 세계 판매
• 가격 동향

제7장 면역측정법 시술

• 기술
• 라벨링 기술
• 효소 면역측정법
• 형광 편광 면역측정법(FPIA)
• 방사면역측정법(RIA)
• 테스트 시술과 제품 판매
• 심장 마커
• 종양마커
• 자가면역질환
• 알레르기 증상
• 갑상선병
• 단백질
• 빈혈
• 불임 검사
• 치료제 모니터링
• 비타민 D
• 당뇨병 /HbA1c
• 남용 약물
• 감염증
• 기기
• 가격 동향

제8장 분자 검사 시술

• 검사 유형
• 테스트 기술
• 감염증
• 혈액검사
• 암
• 이식 매칭
• 혈전 형성성 SNP
• 유전성 질환
• 기타 분자 검사
• 출생전
• 분자 IVD 제품의 세계 판매
• 가격 동향

제9장 검사실에서의 혈액검사 시술

• 검사 유형
• 혈액학 제품의 세계 판매
• 가격 동향

제10장 응고 검사 시술

• 검사 유형
• 응고제 세계 판매
• 가격 동향

제11장 미생물학 검사 시술

• 검사 유형
• ID/AST 자동 패널과 시약
• 매뉴얼 패널과 시약
• 혈액 배양
• 발색성 배지
• 신속 미생물학적 검사
• 질량분석
• 기존 IVD 미생물학 제품의 세계 판매
• ID/AST 패널과 시약
• 혈액 배양
• 발색성 배지
• 신속 미생물학적 검사
• 질량분석
• 가격 동향

제12장 혈액형 판정 시술

• 검사 유형
• 혈액형 판정 제품 판매
• 가격 동향

제13장 조직학/세포학 검사 시술

• 검사 유형
• 면역조직화학 검사
• In Situ 하이브리다이제이션 시험
• 팹 테스트
• 기존 비PAP 염색
• 순환종양세포
• 유세포분석
• 조직학/세포학 IVD 제품 판매
• 가격 동향

제14장 기업 개요

• Abbott Diagnostics
• Core Lab
• i-STAT Business
• Becton, Dickinson and Company(BD)
• bioMerieux Inc.
• BioFire Diagnostics Business
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Danaher Corporation
• Dexcom
• DiaSorin
• Exact Sciences
• Hologic, Inc.
• PANTHER Molecular System
• Illumina
• Natera
• QuidelOrtho Corporation
• The Solana Business
• Revvity
• Roche Diagnostics
• Core Lab
• Core Molecular
• cobas Liat System
• HPV
• 혈액은행
• 이식 의료
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific Inc
• Werfen

문의

KSA

영문 목차

영문목차

Act Now - Be Prepared for Tomorrow's IVD Market

Don't miss your chance to leverage Kalorama Information's expert insights. Equip your business with the knowledge to anticipate changes, optimize product development, and maximize your strategies in the dynamic IVD landscape.

Ready to take action? Purchase the "IVD Test Procedure Volumes, 2024-2029" report today and secure your competitive advantage in this billion-dollar industry.

Kalorama Information's "IVD Test Procedure Volumes, 2024-2029" report provides a deep dive into the global trends shaping in vitro diagnostic (IVD) procedural volumes. Designed to complement Kalorama's comprehensive market analysis in The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 17th Edition, this essential report delivers actionable data on the growth, challenges, and emerging opportunities in the IVD space.

As a rapidly evolving market, the IVD landscape in 2024 is set to thrive, driven by new technologies, evolving healthcare spending, and a surge in demand for precision diagnostics. Our report not only identifies the most significant procedural segments but also breaks down the impact of ongoing innovations.

With this detailed market research, you can stay ahead of industry developments and make informed business decisions. Whether you are looking to expand your product portfolio, explore new market segments, or refine your strategic approach, "IVD Test Procedure Volumes, 2024-2029" offers the data and insights you need to succeed.

Why Choose This Report?

• Comprehensive Market Data
  • Gain an in-depth understanding of IVD procedural volumes by type, region, and country. From self-testing and professional point-of-care (POC) to clinical chemistry, hematology, and beyond-this report covers it all.

• Unmatched Insights into Growth Opportunities
  • Identify high-growth segments by exploring emerging markets and the potential of precision medicine applications.

• Forward-Looking Analysis
  • Understand the trends impacting the IVD market, including shifts in regulatory landscapes, new product developments, and changing disease profiles. This report provides a comprehensive forecast from 2024 to 2029.

• Strategic Guidance for Industry Players
  • Discover how market dynamics, healthcare system trends, and cost pressures are shaping the future of IVD. Use these insights to develop strategies for product positioning, market entry, and growth.

Scope & Methodology

The report includes:

• Global IVD Procedure Volumes by type, covering self and professional POC, clinical chemistry, immunoassay, molecular diagnostics, hematology, coagulation, microbiology, blood banking, and histology/cytology.
• Regional and Country-Specific Data for IVD procedures and their projected growth rates.
• Cost Analysis of various IVD tests to evaluate profitability and potential revenue streams.

Table of Contents

Chapter One: Executive Summary

• IVD Procedure Volume Estimate and Forecast
  • Figure 1-1: Global IVD Procedure Volumes, 2024 and 2029 (in millions # volume)
• Scope & Methodology
• About Kalorama Information

Chapter Two: Introduction

• Overview
• Industry Trends
  • Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
  • Figure 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
• COVID-19
• Demographic Trends
• Global Population and Aging
  • Figure 2-2: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
  • Figure 2-3: Global Population Distribution, 2022
  • Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
• Workforce Reduction
  • Table 2-3: Age Under 15 and Over 65, by Continent, 2020 (Africa, Asia, Europe, Latin America/Caribbean, North America, Oceania)
• Increase in Chronic Diseases
  • Figure 2-4: Leading Causes of Death Globally, by Number of Deaths, 2021 (in millions)
• Personalized Medicine
• New Infectious Disease Threats
  • Table 2-4: Selected Companies Marketing Products Addressing Emerging Infectious Disease Threats
• Tickborne Diseases (TBDs)
• Zika
• Chagas
• Dengue
• Ebola
• Chikungunya
• Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
• Marburg
• SARS-CoV-2 (COVID-19)
• Monkeypox
  • Table 2-5: Selected FDA EUAs for Molecular Diagnostic Tests for Monkeypox
• Emerging and Emerged Markets
  • Table 2-6: Market Potential, by Total Population and Percent Urban, 2023 (population in million) (Brazil; Canada; Chile; China; Colombia; Egypt; India; Malaysia; Mexico; Peru; Poland; Russia; South Africa; South Korea; Saudi Arabia; Turkey; Ukraine; United States; Vietnam)

Chapter Three: IVD Testing Segments

• IVD Testing Trends
  • Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-2: IVD Procedural Volume including Blood Glucose Tests, by Item, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-3: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-4: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-5: IVD Procedural Volume excluding Blood Glucose Tests, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-6: IVD Procedural Volume excluding Blood Glucose Tests, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-7: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-8: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
• Segment Growth Projections
• POC Testing
  • Table 3-5: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
  • Figure 3-9: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
• Clinical Chemistry
  • Table 3-6: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-10: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Immunoassays
  • Table 3-7: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-11: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Mass Spectrometry (Immuno)
  • Table 3-8: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-12: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Molecular Assays
  • Table 3-9: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-13: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Hematology
  • Table 3-10: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-14: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Coagulation
  • Table 3-11: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-15: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Conventional Microbiology
  • Table 3-12: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-16: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Blood Grouping/Typing
  • Table 3-13: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-17: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Histology/Cytology
  • Table 3-14: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
  • Figure 3-18: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
• Segment Product Sales
  • Table 3-15: IVD Product Sales including Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-19: IVD Product Sales including Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-20: IVD Product Sales including Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Table 3-16: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-21: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-22: IVD Product Sales including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Table 3-17: IVD Product Sales excluding Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-23: IVD Product Sales excluding Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-24: IVD Product Sales excluding Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Table 3-18: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-25: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
  • Figure 3-26: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)

Chapter Four: Global IVD Markets

• General
  • Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central, & South America; Middle East; North America [United States; Canada]; Western Europe)
  • Figure 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
  • Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024-2029 (%) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central & South America; Middle East; North America [United States; Canada]; Western Europe)
  • Figure 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024 (%) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
• North America
  • Table 4-3: North America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (Canada, United States)
  • Figure 4-3: North America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions) (Canada, United States)
• United States
• Canada
• Mexico, Central & South America
  • Table 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions)
  • Figure 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
• Brazil
• Mexico
• Other Central & South America
  • Argentina
  • Chile
  • Colombia
  • Peru
  • Venezuela
  • All Other Countries & Territories
• Western Europe
  • Table 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
  • Figure 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
• France
• Germany
• Italy
• Spain
• United Kingdom
• Other Western Europe
  • Austria
  • Belgium
  • Denmark
  • Finland
  • Greece
  • Ireland
  • Norway
  • Netherlands
  • Portugal
  • Sweden
  • Switzerland
  • All Other Countries & Territories
• Eastern Europe
  • Table 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
  • Figure 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
• Russia
• Other Eastern Europe
  • Czech Republic
  • Hungary
  • Poland
  • Romania
  • Ukraine
  • All Other Countries
• Asia/Pacific
  • Table 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (China, Japan, Other Countries & Territories)
  • Figure 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
• China
• Japan
• Other Asian Countries and Territories
  • Australia
  • Hong Kong
  • India
  • Indonesia
  • Malaysia
  • Pakistan
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • New Zealand
  • All Other Countries & Territories
• Middle East
  • Table 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
  • Figure 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
• Turkey
• Other Middle East
  • Iran
  • Iraq
  • Israel
  • Saudi Arabia
  • United Arab Emirates
  • All Other Countries
• Africa
  • Table 4-9: Africa IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
  • Figure 4-9: Africa IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
  • Nigeria
  • South Africa
  • All Other Countries & Territories

Chapter Five: Point-of-Care (POC) Procedures

• Global POC Procedure Volume by Test Type
  • Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2024-2029
  • Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2024-2029
  • Figure 5-1: Regional POC Procedure Volumes excluding blood glucose tests, 2024 (Europe, Japan, United States, Rest of World)
• POC Self Tests
  • Table 5-3: POC Self-Test Procedural Volume, by Type, 2024-2029 (millions) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
• Traditional Blood Glucose Monitoring Activities
• Continuous Blood Glucose Monitoring
• Pregnancy and Fertility Testing
• Coagulation Testing
• Fecal Occult Blood Testing
• Drugs of Abuse Testing
• 1. Pylori Testing
• HIV Testing
• Infectious Disease
• Cholesterol Testing
• POC Urinalysis Testing
• Other POC Self-Testing
• POC Self-Testing Product Sales
  • Table 5-4: POC Self-Test Product Sales, by Type, 2024-2029 ($ million) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
• Pricing Trends
  • Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2024-2029 (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
• POC Professional Testing
  • Table 5-6: POC Professional Procedural Volume, by Type, 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
• POC Professional Blood Glucose Testing Procedures
• POC Professional Critical Care Testing
• POC Fertility Testing
• POC Professional Infectious Disease Testing
• POC Professional Cardiac Marker Testing
• POC Professional Cholesterol/Lipid Testing
• POC Professional Coagulation Testing
• POC Professional HbA1C Testing
• POC Professional Hematology Testing
• POC Professional Fecal Occult Blood Screening
• POC Professional Drugs of Abuse Testing
• POC Professional Urinalysis Testing
• Other POC Professional Testing
• POC IVD Product Sales
  • Table 5-7: POC Professional IVD Product Sales, by Type, 2024-2029 ($ million) (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
• Pricing Trends
  • Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)

Chapter Six: Clinical Chemistry Procedures

• Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2024-2029 (Blood Gas Analysis, General Chemistry, Urinalysis)
• Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
• Types of Tests
• General Chemistry
  • Enzymes
  • Glucose
  • Lipids
  • Proteins
  • Other Compounds
• Blood Gases & Electrolytes
• Urinalysis
• Global Sales of Clinical Chemistry Products
  • Table 6-2: Clinical Chemistry Product Sales, by Type, 2024-2029 ($ million) (Blood Gas Analysis; General Chemistry; Urinalysis)
• Pricing Trends
  • Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2024-2029 (Blood Gas Analysis; General Chemistry; Urinalysis)

Chapter Seven: Immunoassay Procedures

• Technologies
• Labeling Techniques
• Enzyme Immunoassays
• Fluorescence Polarization Immunoassays (FPIAs)
• Radioimmunoassays (RIAs)
  • Table 7-1: Immunoassay Procedural Volume, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
  • Figure 7-1: Regional Immunoassay Procedure Volumes, 2024
• Testing Procedures & Product Sales
  • Table 7-2: Immunoassay Product Sales, by Type, 2024-2029 ($ million) (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
• Cardiac Markers
• Tumor Markers
• Autoimmune Conditions
• Allergy Conditions
• Thyroid Conditions
• Proteins
  • Alzheimer's Disease
• Anemia
• Fertility Testing
• Therapeutic Drug Monitoring
• Vitamin D
• Diabetes/HbA1c
• Drugs of Abuse
• Infectious Diseases
  • Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2024-2029 (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
  • Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
• Instruments
• Pricing Trends
  • Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)

Chapter Eight: Molecular Testing Procedures

• Table 8-1: Molecular Assay Procedural Volume, by Type, 2024-2029 (millions) (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
• Figure 8-1: Regional Molecular Assay Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
• Types of Tests
• Testing Technologies
• Infectious Diseases
  • Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2024-2029 (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
• Blood Screening
• Cancer
• Transplant Matching
• Thrombophilia SNPs
• Inherited Diseases
• Other Molecular Tests
• Prenatal
• Global Sales of Molecular IVD Products
  • Table 8-3: Molecular Assay Product Sales, by Type, 2024-2029 ($ million) (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
  • Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
• Pricing Trends
  • Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2024-2029 (Molecular - Other; Molecular Assays - Oncology; Molecular Blood Bank; Molecular Histology - Non Cancer; Molecular Histology - Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)

Chapter Nine: Laboratory-Based Hematology Procedures

• Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2024-2029 (Complete Blood Count; Other Hematology Tests)
• Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
• Types of Tests
• Global Sales of Hematology Products
  • Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2024-2029 ($ million) (Complete Blood Count; Other Hematology Tests)
• Pricing Trends
  • Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2024-2029 (Complete Blood Count, Other Hematology Tests)

Chapter Ten: Coagulation Testing Procedures

• Table 10-1: Coagulation Procedural Volume, 2024-2029 (D-dimer, PT/INR)
• Figure 10-1: US/ROW Coagulation Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
• Types of Tests
• Global Sales of Coagulation Products
  • Table 10-2: Coagulation Product Sales, 2024-2029 ($ million) (D-dimer, PT/INR)
• Pricing Trends
  • Table 10-3: Coagulation $ Products per Procedure, 2024-2029 (D-dimer, PT/INR)

Chapter Eleven: Microbiology Procedures

• Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2024-2029 (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
• Figure 11-1: Regional Microbiology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
• Types of Tests
• ID/AST Automated Panels & Reagents
• Manual Panels & Reagents
• Blood Culture
• Chromogenic Media
• Rapid Microbiological Tests
• Mass Spectrometry
• Global Sales of Conventional IVD Microbiology Products
• ID/AST Panels & Reagents
• Blood Culture
• Chromogenic Media
• Rapid Microbiological Tests
• Mass Spectrometry
  • Table 11-2: Conventional Microbiology Product Sales, by Type, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
• Pricing Trends
  • Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2024-2029
  • (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)

Chapter Twelve: Blood Grouping/Typing Procedures

• Table 12-1: Blood Grouping/Typing Procedure Volumes, 2024-2029
• Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
• Types of Tests
• Blood Grouping/Typing Product Sales
  • Table 12-2: Blood Grouping/Typing Product Sales, 2024-2029 ($ million)
• Pricing Trends
  • Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2024-2029

Chapter Thirteen: Histology/Cytology Procedures

• Table 13-1: Histology/Cytology Procedural Volume, by Type, 2024-2029 (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
• Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
• Types of Tests
• Immunohistochemistry Tests
• In Situ Hybridization Tests
• Pap Tests
• Traditional Non-Pap Stains
• Circulating Tumor Cells
• Flow Cytometry
• Histology/Cytology IVD Product Sales
  • Table 13-2: Histology/Cytology Product Sales, by Type, 2024-2029 ($ million) (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
• Pricing Trends
  • Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2024-2029

Chapter Fourteen: Company Profiles

• Table 14-1: Revenues of Selected Top 20 IVD Companies, 2023 and estimated 2024 ($ million) (Abbott Diagnostics; Agilent; Becton Dickinson; bioMerieux; Bio-Rad Laboratories; Bruker - CALID; Danaher; Dexcom; DiaSorin; Exact Sciences; Hologic; Illumina; Natera; QuidelOrtho; Revvity; Roche Diagnostics; Siemens Healthineers; Sysmex Corporation; Thermo Fisher Scientific; Werfen)
• Abbott Diagnostics
• Recent Revenue History
  • Table 14-2: Abbott Diagnostic Revenues, 2017-2023 (million $)
• Core Lab
• Hematology
• Blood Banking
• Infectious Diseases - Molecular
• Diabetes
• HIV Point of Care
• i-STAT Business
• COVID-19
• Agilent Technologies
• Recent Revenue History
  • Table 14-3: Agilent Revenues, 2017-2023 (million $)
• Agilent in Genomics
• Cytogenetic Analysis
• Sequencing
• Flow Cytometry
• Companion Diagnostics - Dako
• COVID-19
• Becton, Dickinson and Company (BD)
• Recent Revenue History
  • Table 14-4: BD Diagnostic Revenues, 2017-2023 (million $) FYE Sept 30
• Cytology
• Molecular Microbiology
• Traditional Microbiology - ID/AST
• Blood Culture
• Hospital Acquired Infections
• Blood Collection
• Mass Spectrometry
• COVID-19
• bioMerieux Inc.
• Recent Revenue History
  • Table 14-5: bioMerieux IVD Revenues, 2017-2023 (million $)
• Traditional Microbiology
• Blood Culture
• Immunoassays
• Mass Spectrometry
• BioFire Diagnostics Business
• COVID-19
• Bio-Rad Laboratories, Inc.
• Recent Revenue History
  • Table 14-6: Bio-Rad Diagnostics Revenues, 2017-2023 (million $)
• Blood Bank
• Immunoassays
• COVID-19
• Bruker Corporation
• Recent Revenue History
  • Table 14-7: Bruker Revenue History Product Revenue, 2017-2023 ($ million)
• Acquisitions and Collaborations
• Mass Spectrometry
• Microbiology
• Molecular PCR
• COVID-19
• Danaher Corporation
• Recent Revenue History
  • Table 14-8: Danaher Global IVD Diagnostic Sales, 2017-2023 (million $)
• Dexcom
• Recent Revenue History
  • Table 14-9: Dexcom IVD Diagnostic Sales, 2017-2023 (million $)
• DiaSorin
• Recent Revenue History
  • Table 14-10: DiaSorin Revenues, 2017-2023 (million $)
• Immunoassays
• Molecular
• COVID-19
• Exact Sciences
• Recent Revenue History
  • Table 14-11: Exact Sciences Revenues, 2017-2023 (million $)
• COVID-19
• Hologic, Inc.
• Recent Revenue History
  • Table 14-12: Hologic Revenues, 2017-2023 (million $)
• PANTHER Molecular System
• HIV Testing
• Sexually Transmitted Infections
• Infectious Diseases
• Cytology
• COVID-19
• Illumina
• Recent Revenue History
  • Table 14-13: Illumina Diagnostics Revenues, 2017-2023 (million $)
• COVID-19
• Instrument Laboratory/ Werfen
• Expansion
• Coagulation
• Acute Care
• Natera
• Recent Revenue History
  • Table 14-14: Natera Revenue History 2017-2023 ($ million)
• Prenatal Paternity Testing
• QuidelOrtho Corporation
• Recent Revenue History
  • Table 14-15: QuidelOrtho Revenue History 2018-2023 ($ million)
• Immunoassays
• Rapid Immunoassays
• The Solana Business
• Molecular - Savanna
• Blood Bank
• COVID-19
• Revvity
  • Table 14-16: Revvity Revenue History 2021-2023 ($ million, estimated)
• Roche Diagnostics
• Recent Revenue History
  • Table 14-17: Roche Diagnostics IVD Revenues, 2017-2023 (million $)
• Hematology
• Core Lab
• Immunoassays
• HIV
• Core Molecular
• Digital PCR
• Diabetes Care
• Coagulation
• cobas Liat System - POC
• HPV
• Blood Bank
• Transplant Medicine
• Cancer Companion Testing
• COVID-19
• Siemens Healthineers (Siemens)
• Recent Revenue History
  • Table 14-18: Siemens Healthineers IVD Revenues, 2017-2023 (million $)
• Immunoassays
• Hematology
• Molecular
• Acute Care - POC
• COVID-19
• Sysmex Corporation
• Recent Revenue History
  • Table 14-19: Sysmex IVD Revenues 2018-2023 (million $) FY March 31
• Hematology
• Coagulation
• Urinalysis
• Immunoassays
• Precision Medicine / Companion Test Diagnostics
• Oncology
• COVID-19
• Thermo Fisher Scientific Inc.
• Recent Revenue History
  • Table 14-20: Thermo Fischer IVD Revenues, 2017-2023 (million $)
• Immunoassays
• Microbiology
• Next Generation Sequencing
• Molecular and qPCR
• Mass Spectrometry
• COVID-19
• Werfen
• Recent Revenue History
  • Table 14-21: Werfen IVD Revenues, 2017-2023 (million $)
• Hematology and Coagulation
• Autoimmunity

Contact Us

관련자료